Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
Belviq Breast Cancer Lawsuit Overview:
- Who: Former user of weight loss drug Belviq is suing the drug’s manufacturers and distributors Arena Pharmaceuticals and Eisai Inc.
- Why: The plaintiff alleges the companies failed to adequately test and warn about the drug’s potential breast cancer-causing properties.
- Where: The lawsuit is pending in Missouri federal court.
A Belviq lawsuit alleging the weight loss drug caused cancer will move forward, for the most part, under a new ruling by a Missouri federal judge.
Claims that Arena Pharmaceuticals and Eisai Inc failed to properly warn patients that Arena’s weight loss drug Belviq was linked to breast cancer will reportedly proceed, while others were trimmed.
Belviq Use Linked to Breast Cancer, Claims Lawsuit
The lawsuit, lodged by Missouri resident Amy Davis, alleged her breast cancer diagnosis in November 2019 was caused by her use of Belviq, which she began taking in 2017 to lose weight and for diet control. Davis says language around Belviq did not warn about breast cancer as a side effect, despite mentioning other breast side effects like shrinkage and lactation.
In a recent order, US District Judge Greg Kays allowed Davis’ negligence allegation against Arena which argued that the drug company violated a duty of care it owed to her by not testing Belviq more rigorously for its carcinogenic potential.
On the other hand, Judge Kays dismissed Davis’ “patently incorrect” design defect claims, noting that she failed to identify Arena’s role in manufacturing Belviq and conflated Arena’s and Eisai’s manufacturing roles. He also dismissed a claim of negligent misrepresentation against Eisai.
In early 2020, the US Food and Drug Administration recommended removing Belviq from shelves due to an increased concern of cancer.
To see if you qualify to join a Belviq breast cancer class action lawsuit investigation click here (links to paid attorney advertisement).
The plaintiff is represented by Ryan J. Duplechin and W. Roger Smith III of the Beasley Allen Law Firm and David C. DeGreeff of Wagstaff & Cartmell.
The Belviq Breast Cancer Lawsuit is Davis v. Eisai Inc., et al., Case No. 4:20-cv-00762, in the U.S. District Court for the Western District of Missouri.
Don’t Miss Out!
Check out our list of Class Action Lawsuits and Class Action Settlements you may qualify to join!
Read About More Class Action Lawsuits & Class Action Settlements:
- Grande Cosmetics Enhancement Serums Are Drugs, Not Cosmetics, Class Action Alleges
- Natrol Melatonin Falsely Advertised as ‘Drug-Free,’ Class Action Lawsuit Alleges
- Blood Pressure Drug Recall: Lupin Recalls Tablets After Discovering Human Carcinogen
- Chantix Recall 2021 Prompts Class Action Claims Pfizer Sold ‘Misbranded’ Drug
